Hebei Newtherapy Bio-Pharma Technology

Hebei Newtherapy Bio-Pharma Technology is a clinical-stage biotechnology company headquartered in Shijiazhuang, China, dedicated to the advancement of next-generation immune cell therapies. The company leverages its proprietary platforms to develop Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) therapies targeting a variety of cancers. Its pipeline includes candidates for hematological malignancies, such as B-cell lymphoma and multiple myeloma, as well as solid tumors like liver and gastric cancers. By focusing on innovative targets and optimized cell engineering, Newtherapy seeks to address unmet medical needs in the oncology space through localized R&D and manufacturing.